X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
YUTIQ (fluocinolone acetonide) intravitreal implant 0.18mg is being evaluated in phase 4 clinical trials for the treatment of chronic non-infectious uveitis and related intraocular inflammation.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Yutiq
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
The product ILUVIEN (fluocinolone acetonide) is a sustained release intravitreal implant injected into the back of the eye. ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
Through the divestment, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ® (fluocinolone acetonide) is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Yutiq
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: EyePoint Pharmaceuticals
Deal Size: $82.5 million Upfront Cash: $75.0 million
Deal Type: Divestment May 18, 2023
Details:
Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Europe.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Horus Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023
Details:
Iluvien (fluocinolone acetonide intravitreal implant) is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer injections.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
PALADIN phase 4 data demonstrate ILUVIEN (fluocinolone acetonide) patients experienced on average an increase in visual acuity, a significant decrease in retinal thickness and a predictable and manageable safety profile over 36 months.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The product ILUVIEN (fluocinolone acetonide) is a sustained release intravitreal implant injected into the back of the eye. ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into back of eye,is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce recurrence of disease.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SIFI
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
Iluvien (fluocinolone acetonide intravitreal implant), is designed to release sub-microgram levels, a corticosteroid, for 36 months, to reduce recurrence of disease and number of treatments required, enabling patients to maintain vision longer with fewer injections.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
ILUVIEN (fluocinolone acetonide), sustained release intravitreal implant, demonstrated statistically significant improvements in best-corrected visual acuity, central subfield thickness, also resulted in a 70.5% reduction in treatment burden at 36 months in PALADIN Study.
Lead Product(s): Fluocinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Iluvien
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
